StockNews.com Downgrades Sanofi (NASDAQ:SNY) to Buy

Sanofi (NASDAQ:SNY) was downgraded by equities researchers at StockNews.com from a “strong-buy” rating to a “buy” rating in a research report issued on Tuesday.

A number of other brokerages also recently weighed in on SNY. Argus upped their price target on shares of Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, July 26th. Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Three analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Sanofi currently has an average rating of “Moderate Buy” and an average price target of $57.50.

Sanofi Trading Up 0.5 %

Shares of SNY stock opened at $55.15 on Tuesday. The stock has a market cap of $139.95 billion, a P/E ratio of 28.06, a price-to-earnings-growth ratio of 1.56 and a beta of 0.60. Sanofi has a 1 year low of $42.63 and a 1 year high of $58.97. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The stock has a 50 day simple moving average of $55.64 and a 200 day simple moving average of $51.23.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, July 25th. The company reported $0.93 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.05. The company had revenue of $10.75 billion for the quarter, compared to analyst estimates of $16.86 billion. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. Sanofi’s quarterly revenue was up 7.8% on a year-over-year basis. During the same period in the prior year, the firm posted $0.95 EPS. On average, research analysts predict that Sanofi will post 4.26 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sanofi

Several large investors have recently bought and sold shares of SNY. POM Investment Strategies LLC acquired a new position in shares of Sanofi during the second quarter worth $25,000. Register Financial Advisors LLC bought a new stake in shares of Sanofi in the 1st quarter valued at about $29,000. Larson Financial Group LLC increased its stake in shares of Sanofi by 480.8% in the first quarter. Larson Financial Group LLC now owns 604 shares of the company’s stock valued at $29,000 after buying an additional 500 shares during the period. Palisade Asset Management LLC bought a new position in shares of Sanofi during the first quarter worth about $31,000. Finally, Arrow Financial Corp bought a new position in shares of Sanofi during the second quarter worth about $35,000. 10.04% of the stock is currently owned by institutional investors.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.